573 related articles for article (PubMed ID: 18454684)
1. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
de Visser M; Verwijnen SM; de Jong M
Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and clinical studies of peptide receptor radionuclide therapy.
Pool SE; Krenning EP; Koning GA; van Eijck CH; Teunissen JJ; Kam B; Valkema R; Kwekkeboom DJ; de Jong M
Semin Nucl Med; 2010 May; 40(3):209-18. PubMed ID: 20350630
[TBL] [Abstract][Full Text] [Related]
3. Current status and perspectives in peptide receptor radiation therapy.
Ansquer C; Kraeber-Bodéré F; Chatal JF
Curr Pharm Des; 2009; 15(21):2453-62. PubMed ID: 19601842
[TBL] [Abstract][Full Text] [Related]
4. Peptide-based radiopharmaceuticals for targeted tumor therapy.
Dong C; Liu Z; Wang F
Curr Med Chem; 2014; 21(1):139-52. PubMed ID: 23992337
[TBL] [Abstract][Full Text] [Related]
5. Peptide receptor radionuclide therapy: an overview.
Dash A; Chakraborty S; Pillai MR; Knapp FF
Cancer Biother Radiopharm; 2015 Mar; 30(2):47-71. PubMed ID: 25710506
[TBL] [Abstract][Full Text] [Related]
6. Candidates for peptide receptor radiotherapy today and in the future.
Reubi JC; Mäcke HR; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():67S-75S. PubMed ID: 15653654
[TBL] [Abstract][Full Text] [Related]
7. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
[TBL] [Abstract][Full Text] [Related]
8. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.
van Vliet EI; Teunissen JJ; Kam BL; de Jong M; Krenning EP; Kwekkeboom DJ
Neuroendocrinology; 2013; 97(1):74-85. PubMed ID: 22237390
[TBL] [Abstract][Full Text] [Related]
9. Imaging tumors with peptide-based radioligands.
Behr TM; Gotthardt M; Barth A; Béhé M
Q J Nucl Med; 2001 Jun; 45(2):189-200. PubMed ID: 11476170
[TBL] [Abstract][Full Text] [Related]
10. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
11. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic applications of radiolabeled peptides in nuclear endocrinology.
Behr TM; Béhé M; Becker W
Q J Nucl Med; 1999 Sep; 43(3):268-80. PubMed ID: 10568142
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; de Herder WW; Krenning EP
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
[TBL] [Abstract][Full Text] [Related]
14. Peptide-receptor radionuclide therapy for endocrine tumors.
van Essen M; Krenning EP; Kam BL; de Jong M; Valkema R; Kwekkeboom DJ
Nat Rev Endocrinol; 2009 Jul; 5(7):382-93. PubMed ID: 19488074
[TBL] [Abstract][Full Text] [Related]
15. GEPNETs update: Radionuclide therapy in neuroendocrine tumors.
van der Zwan WA; Bodei L; Mueller-Brand J; de Herder WW; Kvols LK; Kwekkeboom DJ
Eur J Endocrinol; 2015 Jan; 172(1):R1-8. PubMed ID: 25117465
[TBL] [Abstract][Full Text] [Related]
16. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.
Kwekkeboom DJ; Krenning EP; Lebtahi R; Komminoth P; Kos-Kudła B; de Herder WW; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):220-6. PubMed ID: 19713714
[TBL] [Abstract][Full Text] [Related]
17. Radiopeptide imaging and therapy in Europe.
Ambrosini V; Fani M; Fanti S; Forrer F; Maecke HR
J Nucl Med; 2011 Dec; 52 Suppl 2():42S-55S. PubMed ID: 22144555
[TBL] [Abstract][Full Text] [Related]
18. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.
Adant S; Shah GM; Beauregard JM
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):907-921. PubMed ID: 31492995
[TBL] [Abstract][Full Text] [Related]
19. Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy.
Gabriel M; Nilica B; Kaiser B; Virgolini IJ
J Nucl Med; 2019 Apr; 60(4):524-529. PubMed ID: 30115690
[TBL] [Abstract][Full Text] [Related]
20. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.
Van Essen M; Krenning EP; De Jong M; Valkema R; Kwekkeboom DJ
Acta Oncol; 2007; 46(6):723-34. PubMed ID: 17653893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]